NEW ENGLAND JOURNAL OF MEDICINE, vol.383, no.6, pp.546-557, 2020 (Journal Indexed in SCI)
Article / Article
Title of Journal :
NEW ENGLAND JOURNAL OF MEDICINE
BackgroundOfatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.